Leerink Partners resumed coverage on Mannkind with a new price target

9/9/24 7:41:18 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Leerink Partners resumed coverage of Mannkind with a rating of Outperform and set a new price target of $8.00 from $7.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MNKD

Date	Price Target	Rating	Analyst
4/10/2025	$12.00	Outperform	Mizuho
2/10/2025	$11.00	Outperform	Wedbush
12/20/2024	$9.00	Overweight	Wells Fargo
12/19/2024	$7.00 → $10.00	Sector Perform → Outperform	RBC Capital Mkts
9/9/2024	$7.00 → $8.00	Outperform	Leerink Partners
6/13/2024	$8.00	Buy	Rodman & Renshaw
10/10/2023	$10.00	Outperform	Wedbush
2/28/2022	$6.50 → $6.00	Buy	HC Wainwright & Co.